Breaking News

Aji Bio-Pharma, DNDi Enter Strategic Supply Pact

Aji Bio-Pharma will manufacture CpG-D35, a class of CpG oligonucleotides to be used in the treatment of cutaneous leishmaniasis infections.

By: Contract Pharma

Contract Pharma Staff

Ajinomoto Bio-Pharma Services (Aji Bio-Pharma), a provider of biopharmaceutical contract development and manufacturing services, has entered into a strategic supply partnership with the Drugs for Neglected Disease Initiative (DNDi), for the supply of a CpG oligonucleotide, as part of a combination therapy used in the treatment of cutaneous leishmaniasis infections. This project is supported by the Global Health Innovative Technology (GHIT) Fund. Aji Bio-Pharma will manufacture CpG-D35, a cla...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters